In 2021, based on a phase 2 trial, the U.S. Food and Drug Administration (FDA) accelerated the approval of Sotorasib as the first KRAS G12C blocking drug for treatment of adult patients with NSCLC [20]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.